Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 6011-6020

  Carneiro, Guilherme ^a   Silva, Elton Luiz ^a   Pacheco, Layssa Alves ^a   de Souza Fagundes, Elaine Maria ^a   Corrêa, Natássia Caroline Resende ^a   de Goes, Alfredo Miranda ^a   de Oliveira, Mônica Cristina ^a   Ferreira, Lucas Antônio Miranda ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

All trans retinoic acid; Antitumor activity; Cancer; Ion pairing; Solid lipid nanoparticles; Treatment

Indexed keywords

AMINE; BENETHAMINE; OCTADECYLAMINE; RETINOIC ACID; SOLID LIPID NANOPARTICLE; TRIETHYLAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ION; LIPID; NANOCAPSULE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; LIPOPHILICITY; PARTICLE SIZE; ZETA POTENTIAL; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; DIFFUSION; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLIZATION; DIFFUSION; DRUG SYNERGISM; HUMANS; IONS; LIPIDS; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME; TRETINOIN;

EID: 84875829715     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S38953     Document Type: Article

References (40)

1. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol. 2011;6:345-364.
2. Niles RM. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res. 2004;555(1-2):81-96.
3. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv DrugDelivRev. 2010;62(13):1285-1298.
4. Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG. Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst. 1993;85(12):993-996.
5. Muindi JR, Frankel SR, Huselton C, et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992;52(8):2138-2142.
6. Abdulmajed K, Heard CM. Topical delivery of retinyl ascorbate co-drug. 1. Synthesis, penetration into and permeation across human skin. Int J Pharm. 2004;280(1-2):113-124.
7. Chung KD, Jeong YI, Chung CW, Kim do H, Kang DH. Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanopar-ticles against HuCC-T1 human cholangiocarcinoma cells. Int J Pharm. 2012;422(1-2):454-461.
8. Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release. 2004;100(1):53-61.
9. Chansri N, Kawakami S, Yamashita F, Hashida M. Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. Int J Pharm. 2006;321(1-2):42-49.
10. Kawakami S, Suzuki S, Yamashita F, Hashida M. Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release. 2006;110(3): 514-521.
11. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
12. Jenning V, Lippacher A, Gohla SH. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. JMicroencapsul. 2002;19(1):1-10.
13. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161-172.
14. Jenning V Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18(2):149-158.
15. Lim SJ, Kim CK. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm. 2002;243(1-2):135-146.
16. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004; 56(12):1527-1535.
17. Kayali I, Ward AJ, Suhery T, Friberg SE, Simion A, Rhein LD. Interactions of retinoic acid with a model of stratum corneum lipids. J Dermatol Clin Eval Soc. 1991;2:7-17.
18. Castro GA, Orefice RL, Vilela JM, Andrade MS, Ferreira LA. Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. J Microencapsul. 2007;24(5): 395-407.
19. Castro GA, Coelho AL, Oliveira CA, Mahecha GA, Orefice RL, Ferreira LA. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm. 2009;381(1): 77-83.
20. Souza-Fagundes EM, Queiroz AB, Martins Filho OA, et al. Screening and fractionation of plant extracts with antiproliferative activity on human peripheral blood mononuclear cells. Mem Inst Oswaldo Cruz. 2002;97(8):1207-1212.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
22. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458-1461.
23. Munster U, Nakamura C, Haberland A, et al. RU 58841-myristate -prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie. 2005;60(1):8-12.
24. Schafer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59(6):427-443.
25. Fanjul AN, Bouterfa H, Dawson M, Pfahl M. Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res. 1996;56(7): 1571-1577.
26. Hong TK, Lee-Kim YC. Effects of retinoic acid isomers on apoptosis and enzymatic antioxidant system in human breast cancer cells. Nutr Res Pract. 2009;3(2):77-83.
27. Roberts WR, Addy M. Comparison of the in vivo and in vitro antibacterial properties of antiseptic mouthrinses containing chlorhexidine, alexidine, cetyl pyridinium chloride and hexetidine. Relevance to mode of action. J Clin Periodontal. 1981;8(4):295-310.
28. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994;11(8):1127-1131.
29. Scholer N, Olbrich C, Tabatt K, Muller RH, Hahn H, Liesenfeld O. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm. 2001; 221(1-2):57-67.
30. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp Cell Res. 1997;234(2):293-299.
31. Mangiarotti R, Danova M, Alberici R, Pellicciari C. All-trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. Br J Cancer. 1998;77(2):186-191.
32. Hwang SR, Lim SJ, Park JS, Kim CK. Phospholipid-based microemulsion formulation of all-trans-retinoic acid for parenteral administration. Int J Pharm. 2004;276(1-2):175-183.
33. Su J, Zhang N, Ho PC. Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. J Pharm Sci. 2008;97(7): 2844-2853.
34. Chen ZX, Breitman TR. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res. 1994;54(13):3494-3499.
35. Giermasz A, Nowis D, Jalili A, et al. Antitumor activity of tributyrin in murine melanoma model. Cancer Lett. 2001;164(2):143-148.
36. Lengsfeld CS, Pitera D, Manning M, Randolph TW. Dissolution and partitioning behavior of hydrophobic ion-paired compounds. Pharm Res. 2002;19(10):1572-1576.
37. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1-2):216-227.
38. Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004;58(3):673-680.
39. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev DrugDiscov. 2007;6(10):793-810.
40. Bonet ML, Ribot J, Palou A. Lipid metabolism in mammalian tissues and its control by retinoic acid. Biochim Biophys Acta. 2012;1821(1): 177-189.